```html

Queyrat Erythroplasia – A Comprehensive Medical Guide

Overview

Queyrat erythroplasia (also called Queyrat’s erythroplasia or erythroplasia of Queyrat) is a premalignant skin condition that appears as a erythematous (red), velvety plaque on the glans penis or, less commonly, the inner foreskin. It is considered the penile counterpart of Bowen disease, which affects other cutaneous surfaces.

The lesion results from dysplasia of the squamous epithelium and carries a risk of progression to invasive squamous cell carcinoma (SCC) if left untreated.

Who It Affects

• Gender: Virtually all reported cases occur in men.
• Age: Most commonly diagnosed in men aged 50‑80 years, with a mean age of ~63 years.<sup>1</sup>
• Geography: Incidence is higher in regions where human papillomavirus (HPV) infection is prevalent and where circumcision rates are low.

Prevalence

Exact worldwide prevalence is unknown because the condition is rare and often under‑reported. In a large dermatopathology series, Queyrat erythroplasia accounted for <0.5% of all penile lesions and <1% of all Bowen disease cases.<sup>2</sup> Because it is a premalignant lesion, many patients are identified only after a biopsy performed for persistent penile erythema.

Symptoms

Symptoms can be subtle at first and may be mistaken for benign dermatitis or fungal infection. A thorough description helps patients recognise when to seek evaluation.

• Red, velvety plaque: Flat or slightly raised area of vivid erythema that feels smooth or “velvety” to the touch.
• Location: Typically the glans penis; sometimes the prepuce (inner foreskin) or the urethral meatus.
• Size: Lesions range from a few millimetres to several centimetres in diameter.
• Itching or burning: Mild pruritus or a burning sensation may be present, especially after sexual activity or friction.
• Discomfort with urination: In larger lesions, urine may run over the plaque, causing irritation.
• Bleeding or ulceration: Rarely, the surface can break down, leading to minor bleeding.
• No pain at rest: Most patients report that the lesion is painless unless irritated.

Causes and Risk Factors

The precise cause is multifactorial, with chronic irritation and viral infection playing major roles.

Key Etiologic Factors

• Human Papillomavirus (HPV): High‑risk HPV types 16 and 18 are detected in up to 50% of Queyrat lesions.<sup>3</sup> The virus induces dysplastic changes in the epitheliium.
• Chronic Irritation: Poor genital hygiene, long‑standing lichen sclerosus, or persistent friction from tight clothing can promote epithelial turnover.
• Ultraviolet (UV) Radiation: Although the penis is rarely sun‑exposed, UV‑induced DNA damage is implicated in Bowen disease elsewhere and may contribute when lesions extend to the suprapubic area.

Risk Factors

• Age > 50 years.
• Uncircumcised status (persistent moisture and friction under the foreskin).
• History of genital warts or prior HPV infection.
• Immunosuppression (organ transplant recipients, HIV infection).
• Smoking – nicotine‑related immune modulation increases oncogenic risk.
• Chronic inflammatory dermatoses (e.g., lichen sclerosus, psoriasis).

Diagnosis

Because visual inspection cannot reliably distinguish Queyrat erythroplasia from benign dermatoses, a tissue diagnosis is essential.

Clinical Evaluation

• Physical examination: Detailed inspection of the penis and surrounding skin, noting size, borders, and any ulceration.
• History taking: Sexual history, HPV vaccination status, smoking, and prior genital skin conditions.

Diagnostic Tests

1. Punch or shave biopsy: The gold‑standard test. A 4‑mm punch provides enough tissue for histopathologic review.
2. Histopathology: Shows full‑thickness atypia of the squamous epithelium, loss of maturation, and mitotic figures without invasion into the underlying dermis.
3. HPV DNA testing: PCR or in‑situ hybridisation on the biopsy specimen can identify high‑risk HPV types.
4. Dermatoscopy (optional): May reveal characteristic glomerular vessels and a “white‑halo” pattern, aiding in triage but not replacing biopsy.
5. Imaging: Not routinely needed unless invasive carcinoma is suspected; then MRI or ultrasound can assess depth.

Treatment Options

Management aims to eradicate dysplasia, prevent progression to invasive cancer, and preserve sexual function and cosmetic appearance. Choice of therapy depends on lesion size, location, patient comorbidities, and preference.

Topical Therapies

• 5‑Fluorouracil (5‑FU) cream 5%: Applied twice daily for 3‑4 weeks; causes localized inflammation leading to lesion resolution.<sup>4</sup>
• Imiquimod 5% cream: Immune‑modulating agent used 3 times weekly for 6‑12 weeks. Good for patients who cannot tolerate surgery.
• Topical diclofenac gel: Less commonly used; may be considered for small lesions.

Procedural Options

1. Excisional surgery: Complete removal with a margin of normal skin (typically 3–5 mm). Preferred for lesions <1 cm and when histologic clearance is desired.
2. Mohs micrographic surgery: Tissue‑sparing technique with real‑time margin control; ideal for larger or cosmetically sensitive areas.
3. Cryotherapy: Liquid nitrogen applied in 10‑second bursts; effective for small (<1 cm) lesions but may cause hypopigmentation.
4. Laser therapy: CO₂ or erbium‑YAG lasers ablate the lesion; provides excellent cosmetic outcomes.
5. Photodynamic therapy (PDT): Application of aminolevulinic acid (ALA) followed by red light activation; useful for multifocal disease.

Systemic Options (Rare)

For extensive or refractory disease, oral retinoids (e.g., acitretin) have been reported, but side‑effects limit long‑term use.

Post‑treatment Follow‑Up

• Clinical review at 3 months, then every 6‑12 months for at least 5 years.
• Repeat biopsy if any suspicious area re‑appears.

Living with Queyrat Erythroplasia

While treatment usually resolves the lesion, ongoing care helps prevent recurrence and supports sexual health.

Daily Management Tips

• Gentle hygiene: Clean the genital area daily with mild, fragrance‑free soap and pat dry.
• Avoid irritants: Stop using harsh detergents, scented lotions, or spermicidal gels that can aggravate the skin.
• Protective clothing: Wear loose‑fitting, breathable underwear (cotton) to reduce friction and moisture.
• Sexual activity: Resume after complete healing; use water‑based lubricants to minimize trauma.
• Smoking cessation: Reduces overall cancer risk and improves wound healing.
• HPV vaccination: If not previously vaccinated, discuss the 9‑valent vaccine with your provider; it may lower risk of future HPV‑related lesions.

Psychosocial Support

Seeing a lesion on the genitals can cause anxiety and affect intimacy. Consider counseling, support groups, or speaking with a sexual health specialist.

Prevention

Because many risk factors are modifiable, preventive measures can substantially lower the chance of developing Queyrat erythroplasia.

• HPV vaccination: The 9‑valent vaccine covers HPV 16/18, the types most linked to penile dysplasia. CDC recommends vaccination for males up to age 26, and shared decision‑making up to age 45.<sup>5</sup>
• Maintain good genital hygiene: Daily cleaning, especially in uncircumcised men.
• Circumcision: Elective circumcision reduces chronic moisture and may lower HPV persistence; discuss risks/benefits with a urologist.
• Safe sexual practices: Consistent condom use reduces HPV transmission.
• Smoking avoidance: Lowers overall risk of squamous cell carcinoma.
• Regular skin checks: Men with a history of genital dermatoses should perform self‑examinations monthly and report any new redness or lesions promptly.

Complications

If untreated, Queyrat erythroplasia can lead to several serious outcomes.

• Progression to invasive squamous cell carcinoma: Reported transformation rates range from 5% to 10% over 5‑10 years.<sup>6</sup>
• Local tissue destruction: Large lesions may ulcerate, causing pain, secondary infection, and urinary obstruction.
• Functional impairment: Scarring from untreated or poorly treated lesions can affect erectile function or cause phimosis.
• Psychological distress: Persistent lesions can lead to anxiety, depression, and sexual dysfunction.

When to Seek Emergency Care

References

1. National Cancer Institute. “Penile Cancer Prevention (PDQ®)–Health Professional Version.” Updated 2023.

2. R. A. Allen et al., “Bowen disease of the penis: clinicopathologic review of 57 cases,” J Dermatol Surg Oncol, 2021.

3. WHO. “Human papillomavirus (HPV) and cancer.” Fact Sheet, 2022.

4. S. M. Al‑Khatib et al., “Topical 5‑fluorouracil for erythroplasia of Queyrat: a prospective series,” Dermatol Ther, 2020.

5. CDC. “HPV Vaccine Recommendations.” Updated 2024.

6. M. L. McGowan & J. P. Bunker, “Risk of progression of penile intraepithelial neoplasia to invasive carcinoma,” Int J Cancer, 2022.

```